| EGFR-TKI治疗非小细胞肺癌研究进展 |
| |
| 引用本文： | 林英城,林雯,王鸿彪,李德锐.EGFR-TKI治疗非小细胞肺癌研究进展[J].国外医学(肿瘤学分册),2007(6). |
| |
| 作者姓名： | 林英城 林雯 王鸿彪 李德锐 |
| |
| 作者单位： | 汕头大学医学院附属肿瘤医院内科，汕头大学医学院附属肿瘤医院内科，汕头大学医学院附属肿瘤医院内科，汕头大学医学院附属肿瘤医院内科 |
| |
| 摘 要： | 吉非替尼和厄洛替尼均为小分子量表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI),已在化疗失败的晚期非小细胞肺癌(NSCLC)解救治疗中取得疗效,但仅对特定人群发挥作用。EGFR- TKI联合化疗一线治疗NSCLC并未能提高疗效;正在进行的临床研究聚焦于优势人群EGFR-TKI一线治疗或联合化疗的研究。
|
| 关 键 词： | 癌 非小细胞肺 受体 表皮生长因子 受体蛋白酪氨酸激酶类 药物疗法 |
Progression in EGFR-TKI for non-small cell lung cancer |
| |
| LIN Ying-cheng,LIN Wei,WANG Hong-biao.Medical Oncology,Cancer Hospital,Shantou University Medical College,Shantou ,China.Progression in EGFR-TKI for non-small cell lung cancer[J].Foreign Medical Sciences (Cancer Section),2007(6). |
| |
| Authors: | LIN Ying-cheng LIN Wei WANG Hong-biaoMedical Oncology Cancer Hospital Shantou University Medical College Shantou China |
| |
| Institution: | LIN Ying-cheng,LIN Wei,WANG Hong-biao.Medical Oncology,Cancer Hospital,Shantou University Medical College,Shantou 515031,China |
| |
| Abstract: | Both gefitinib and erlotinib are small molecular epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI). They are effective for patients with previously treated advanced non-small-cell lung cancer ( NSCLC), but only in certain subsets of patients. No survival advantage is seen with concurrent chemotherapy of gefitinib and erlotinib as first-line treatment of advanced NSCLC. Ongoing studies focus on EGFR-TKI alone or combination chemotherapy as first line therapy in benefit population. |
| |
| Keywords: | Carcinoma no-small-cell lung Receptor epidermal growth factor Receptor protein-tyro-sine kinase Drug therapy |
| 本文献已被 CNKI 等数据库收录！ |
